Výsledky vyhledávání - "Friedland DM"

Akademický článek

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.

Autor: Villaruz LC; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh., Wang X; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham., Bertino EM; Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus., Gu L; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham., Antonia SJ; Duke Cancer Institute, Durham, USA., Burns TF; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh., Clarke J; Duke Cancer Institute, Durham, USA., Crawford J; Duke Cancer Institute, Durham, USA., Evans TL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh., Friedland DM; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh., Otterson GA; Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus., Ready NE; Duke Cancer Institute, Durham, USA., Wozniak AJ; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh., Stinchcombe TE; Duke Cancer Institute, Durham, USA. Electronic address: Thomas.stinchcombe@duke.edu.

Publikováno v: ESMO open [ESMO Open] 2023 Apr; Vol. 8 (2), pp. 101183. Date of Electronic Publication: 2023 Mar 09.

Zobrazit plný text záznamu

Akademický článek

First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC.

Autor: Ancevski Hunter K; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Friedland DM; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Villaruz LC; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Burns TF; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: burnstf@upmc.edu.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2018 Jan; Vol. 13 (1), pp. e3-e5. Date of Electronic Publication: 2017 Oct 05.

Zobrazit plný text záznamu

Akademický článek

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Autor: Tarhini AA; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Rafique I; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Floros T; Department of Medicine, Athens Naval & Veterans Hospital, Athens, Greece., Tran P; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Gooding WE; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Villaruz LC; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Burns TF; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.; Department of Medicine, Athens Naval & Veterans Hospital, Athens, Greece., Friedland DM; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Petro DP; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Farooqui M; Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota., Gomez-Garcia J; Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota., Gaither-Davis A; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania., Dacic S; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Argiris A; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Socinski MA; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania., Stabile LP; University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh, Pennsylvania.; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania., Siegfried JM; Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.

Publikováno v: Cancer [Cancer] 2017 Aug 01; Vol. 123 (15), pp. 2936-2944. Date of Electronic Publication: 2017 May 04.

Zobrazit plný text záznamu

Akademický článek

Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer.

Autor: Bernard ME; Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA., Glaser SM; Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA., Gill BS; Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA., Beriwal S; Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA., Heron DE; Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA., Luketich JD; Department of Thoracic Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA , USA., Friedland DM; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center , Pittsburgh, PA , USA., Socinski MA; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center , Pittsburgh, PA , USA., Greenberger JS; Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.

Publikováno v: Frontiers in oncology [Front Oncol] 2017 Jan 23; Vol. 7, pp. 1. Date of Electronic Publication: 2017 Jan 23 (Print Publication: 2017).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání